Immune-based therapies for hepatocellular carcinoma

被引：181

作者：

Pinato, David J. ^{[1
]}

Guerra, Nadia ^{[2
]}

Fessas, Petros ^{[1
]}

Murphy, Ravindhi ^{[1
]}

Mineo, Takashi ^{[3
]}

Mauri, Francesco A. ^{[1
]}

Mukherjee, Sujit K. ^{[4
]}

Thursz, Mark ^{[4
]}

Wong, Ching Ngar ^{[1
]}

Sharma, Rohini ^{[1
]}

Rimassa, Lorenza ^{[5
,6
]}

机构：

[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England

[2] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England

[3] Tokyo Med & Dent Univ, Tokyo, Japan

[4] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England

[5] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy

[6] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy

来源：

ONCOGENE | 2020年 / 39卷 / 18期

基金：

英国惠康基金;

关键词：

REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; PHASE-III; TGF-BETA; ADOPTIVE IMMUNOTHERAPY;

D O I：

10.1038/s41388-020-1249-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

引用

页码：3620 / 3637

页数：18

共 50 条

[1] Immune-based therapies for hepatocellular carcinoma
David J. Pinato
Nadia Guerra
Petros Fessas
Ravindhi Murphy
Takashi Mineo
Francesco A. Mauri
Sujit K. Mukherjee
Mark Thursz
Ching Ngar Wong
Rohini Sharma
Lorenza Rimassa
Oncogene, 2020, 39 : 3620 - 3637
[2] Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, Tim F.
Lai, Chunwei Walter
Li, Guangfu
Staveley-O'Carroll, Kevin F.
GASTROENTEROLOGY, 2019, 156 (02) : 510 - 524
[3] Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
Carloni, Riccardo
Sabbioni, Simone
Rizzo, Alessandro
Ricci, Angela Dalia
Palloni, Andrea
Petrarota, Cataldo
Cusmai, Antonio
Tavolari, Simona
Gadaleta-Caldarola, Gennaro
Brandi, Giovanni
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1445 - 1463
[4] Current status and perspectives of immune-based therapies for hepatocellular carcinoma
Aerts, Maridi
Benteyn, Daphne
Van Vlierberghe, Hans
Thielemans, Kris
Reynaert, Hendrik
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (01) : 253 - 261
[5] Current status and perspectives of immune-based therapies for hepatocellular carcinoma
Maridi Aerts
Daphné Benteyn
Hans Van Vlierberghe
Kris Thielemans
Hendrik Reynaert
World Journal of Gastroenterology, 2016, (01) : 253 - 261
[6] Targeted and Immune-Based Therapies for Hepatocellular Carcinoma (vol 156, pg 510, 2019)
Greten, T. F.
Lai, C. W.
Li, G.
GASTROENTEROLOGY, 2024, 167 (04) : 819 - 819
[7] Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma
Xue, Chen
Gu, Xinyu
Li, Lanjuan
CANCER CELL INTERNATIONAL, 2021, 21 (01)
[8] Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma
Chen Xue
Xinyu Gu
Lanjuan Li
Cancer Cell International, 21
[9] Immune-based therapies for childhood cancer
Mackall, Crystal L.
Merchant, Melinda S.
Fry, Terry J.
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (12) : 693 - 703
[10] ANTIRETROVIRAL AND IMMUNE-BASED THERAPIES - UPDATE
YENI, P
SCHOOLEY, R
HAMMER, S
AIDS, 1993, 7 : S173 - S184

← 1 2 3 4 5 →